Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00307801
Registration number
NCT00307801
Ethics application status
Date submitted
27/03/2006
Date registered
28/03/2006
Date last updated
30/12/2014
Titles & IDs
Public title
Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding
Query!
Scientific title
A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.
Query!
Secondary ID [1]
0
0
2005-004340-32
Query!
Secondary ID [2]
0
0
91470
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metrorrhagia
0
0
Query!
Condition category
Condition code
Renal and Urogenital
0
0
0
0
Query!
Other renal and urogenital disorders
Query!
Reproductive Health and Childbirth
0
0
0
0
Query!
Menstruation and menopause
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
Treatment: Drugs - Placebo
Experimental: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) - A blister consists of 28 tablets taken orally once a day for 28 days (one cycle): 2 days of 3 mg estradiol valerate (EV); 5 days of 2 mg EV + 2 mg dienogest (DNG); 17 days of 2 mg EV + 3 mg DNG; 2 days of 1 mg EV; 2 days of placebo.
Placebo comparator: Placebo - Matching placebo to be taken orally daily.
Treatment: Drugs: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)
1 pill per day taken orally over 7 cycles of 28 pills per cycle
Treatment: Drugs: Placebo
1 pill per day taken orally over 7 cycles of 28 pills per cycle
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms
Query!
Assessment method [1]
0
0
At least 6, up to 8 criteria to be met in complete response during 90-day period: no bleeding episodes(BE) \>7 days, no \>4 BE, no BE with blood loss (menstrual blood loss, MBL) =80 mL, no \>1 BE increase from baseline, no increase from baseline in individual patient's total number of bleeding days and total number of bleeding days not \>24 days. Additionally, for subjects included with prolonged bleeding: decrease between maximum duration during run-in and efficacy =2 days excessive bleeding: MBL associated with each episode decreased by =50% from average of qualifying episodes during run-in.
Query!
Timepoint [1]
0
0
Efficacy phase was defined as a 90-day period under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7
Query!
Secondary outcome [1]
0
0
Proportion of Participants Cured From Prolonged Bleeding
Query!
Assessment method [1]
0
0
Prolonged bleeding: 2 or more bleeding episodes, each lasting 8 or more days. Cure from prolonged bleeding: no bleeding episodes lasting more than 7 days and the decrease between maximum duration during run-in and maximum duration during the efficacy phase was at least 2 days.
Query!
Timepoint [1]
0
0
Efficacy phase was defined as a 90-day period under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7
Query!
Secondary outcome [2]
0
0
Proportion of Participants Cured From Excessive Bleeding
Query!
Assessment method [2]
0
0
Excessive bleeding:\>=2 bleeding episodes each with blood loss volume (MBL) of \>=80 mL in 90-day period, assessed by alkaline hematin method. This spectrophotometrical method measures hemoglobin (Hb) in fixed amount of alkaline solution, taken from pool of solution in which materials (used sanitary protection) to be tested have been macerated for Hb extraction. Cure from excessive bleeding: MBL in each episode \<80 mL + blood loss volume associated with each bleeding episode is decrease of =50% from average of qualifying bleeding episodes (with blood loss volume =80 mL per episode during run-in)
Query!
Timepoint [2]
0
0
Efficacy phase was defined as a 90-day period under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7
Query!
Secondary outcome [3]
0
0
Proportion of Participants Cured From Frequent Bleeding
Query!
Assessment method [3]
0
0
Frequent bleeding: greater than 5 bleeding episodes, with a minimum of 20 bleeding days overall. Cure from frequent bleeding: no more than 4 bleeding episodes and the total number of bleeding days did not exceed 24 days and no increase from baseline in an individual patient's total number of bleeding days occurred
Query!
Timepoint [3]
0
0
Efficacy phase was defined as a 90-day period under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7
Query!
Secondary outcome [4]
0
0
Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 84
Query!
Assessment method [4]
0
0
According to the investigator's global assessment scale "improved" was defined as being classified as 'very much improved', 'much improved', or 'improved' and "not improved" was defined as being classified as 'no change', 'worse', 'much worse', 'very much worse', or 'not assessed'. Central laboratory data, physical examination, e-diary data, and patient interview were used as sources for the assessment at day 84 compared with admission to study data.
Query!
Timepoint [4]
0
0
From baseline (visit 5, day 1) up to treatment day 84
Query!
Secondary outcome [5]
0
0
Proportion of Participants With Improvement in the Investigator's Global Assessment Scale at Treatment Day 196
Query!
Assessment method [5]
0
0
According to the investigator's global assessment scale "improved" was defined as being classified as 'very much improved', 'much improved', or 'improved' and "not improved" was defined as being classified as 'no change', 'worse', 'much worse', 'very much worse', or 'not assessed'. Central laboratory data, physical examination, e-diary data, and patient interview were used as sources for the assessment at day 196 compared with admission to study data.
Query!
Timepoint [5]
0
0
From baseline (visit 5, day 1) up to treatment day 196
Query!
Secondary outcome [6]
0
0
Proportion of Participants With Improvement in the Patient's Overall Assessment Scale at Treatment Day 84
Query!
Assessment method [6]
0
0
According to the patient's global assessment scale "improved" was defined as being classified as 'very much improved', 'much improved', or 'improved' and "not improved" was defined as being classified as 'no change', 'worse', 'much worse', 'very much worse', or 'not assessed'. Patients assessed the overall improvement at day 84 compared with admission to the study condition.
Query!
Timepoint [6]
0
0
From baseline (visit 5, day 1) up to treatment day 84
Query!
Secondary outcome [7]
0
0
Proportion of Participants With Improvement in the Patient's Overall Assessment Scale at Treatment Day 196
Query!
Assessment method [7]
0
0
According to the patient´s global assessment scale "improved" was defined as being classified as 'very much improved', 'much improved', or 'improved' and "not improved" was defined as being classified as 'no change', 'worse', 'much worse', 'very much worse', or 'not assessed'. Patients assessed the overall improvement at day 196 compared with admission to the study condition.
Query!
Timepoint [7]
0
0
From baseline (visit 5, day 1) up to treatment day 196
Query!
Secondary outcome [8]
0
0
Change From Baseline in Blood Loss Volume for All Participants to the Reference Period of 90 Days Under Treatment
Query!
Assessment method [8]
0
0
Menstrual blood loss volume as assessed by the alkaline hematin method for the 90 days before treatment (baseline) and for 90 days under treatment. This spectrophotometrical method measures hemoglobin (Hb) in fixed amount of alkaline solution, taken from pool of solution in which materials (used sanitary protection) to be tested have been macerated for Hb extraction. A negative value indicates a reduction in blood loss after treatment.
Query!
Timepoint [8]
0
0
Baseline and reference period of 90 days under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7
Query!
Secondary outcome [9]
0
0
Menstrual Blood Loss Volume for All Participants at Cycle 1
Query!
Assessment method [9]
0
0
Menstrual blood loss volume as assessed by the alkaline hematin method after patients were on treatment for one cycle. This spectrophotometrical method measures hemoglobin (Hb) in fixed amount of alkaline solution, taken from pool of solution in which materials (used sanitary protection) to be tested have been macerated for Hb extraction.
Query!
Timepoint [9]
0
0
Cycle 1 = 28 days (one cycle)
Query!
Secondary outcome [10]
0
0
Menstrual Blood Loss Volume for All Participants at Cycle 3
Query!
Assessment method [10]
0
0
Menstrual blood loss volume as assessed by the alkaline hematin method after patients were on treatment for 3 cycles. This spectrophotometrical method measures hemoglobin (Hb) in fixed amount of alkaline solution, taken from pool of solution in which materials (used sanitary protection) to be tested have been macerated for Hb extraction.
Query!
Timepoint [10]
0
0
Cycle 3 = 28 days (one cycle)
Query!
Secondary outcome [11]
0
0
Menstrual Blood Loss Volume for All Participants at Cycle 7
Query!
Assessment method [11]
0
0
Menstrual blood loss volume as assessed by the alkaline hematin method after patients were on treatment for 7 cycles. This spectrophotometrical method measures hemoglobin (Hb) in fixed amount of alkaline solution, taken from pool of solution in which materials (used sanitary protection) to be tested have been macerated for Hb extraction.
Query!
Timepoint [11]
0
0
Cycle 7 = 28 days (one cycle)
Query!
Secondary outcome [12]
0
0
Change From Baseline in Blood Loss Volume for Participants With Excessive Bleeding to the Reference Period of 90 Days Under Treatment.
Query!
Assessment method [12]
0
0
Blood loss volume as assessed by the alkaline hematin method for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 ml or more during the run-in phase) for the 90 days before treatment (ie, run-in phase) and for the 90 days under treatment. A negative value indicates a reduction in blood loss while under treatment compared to before treatment.
Query!
Timepoint [12]
0
0
Baseline and reference period of 90 days under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7
Query!
Secondary outcome [13]
0
0
Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 1.
Query!
Assessment method [13]
0
0
Blood loss volume as assessed by the alkaline hematin method for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 ml or more during the run-in phase) after participants were on treatment for one cycle. This spectrophotometrical method measures hemoglobin (Hb) in fixed amount of alkaline solution, taken from pool of solution in which materials (used sanitary protection) to be tested have been macerated for Hb extraction.
Query!
Timepoint [13]
0
0
Cycle 1 = 28 days (one cycle)
Query!
Secondary outcome [14]
0
0
Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 3.
Query!
Assessment method [14]
0
0
Blood loss volume as assessed by the alkaline hematin method for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 ml or more during the run-in phase) after participants were on treatment for 3 cycles. This spectrophotometrical method measures hemoglobin (Hb) in fixed amount of alkaline solution, taken from pool of solution in which materials (used sanitary protection) to be tested have been macerated for Hb extraction.
Query!
Timepoint [14]
0
0
Cycle 3 = 28 days (one cycle)
Query!
Secondary outcome [15]
0
0
Menstrual Blood Loss Volume for Participants With Excessive Bleeding at Cycle 7.
Query!
Assessment method [15]
0
0
Blood loss volume as assessed by the alkaline hematin method for participants with excessive bleeding (2 or more bleeding episodes each with blood loss volume of 80 ml or more during the run-in phase) after participants were on treatment for 7 cycles. This spectrophotometrical method measures hemoglobin (Hb) in fixed amount of alkaline solution, taken from pool of solution in which materials (used sanitary protection) to be tested have been macerated for Hb extraction.
Query!
Timepoint [15]
0
0
Cycle 7 = 28 days (one cycle)
Query!
Secondary outcome [16]
0
0
Change From Baseline in Number of Bleeding Episodes to the Reference Period of 90 Days Under Treatment
Query!
Assessment method [16]
0
0
A bleeding episode is characterized by the following: • Bleeding for at least 2 days • Bleeding days can be separated by no more than 1 bleeding-free day • An episode stops with 2 consecutive bleeding-free days. The number of episodes was determined for the 90 days before treatment and for the 90 days under treatment. negative value indicates a reduction from baseline in the number of episodes while under treatment.
Query!
Timepoint [16]
0
0
Baseline and reference period of 90 days under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7
Query!
Secondary outcome [17]
0
0
Change From Baseline in Number of Bleeding Days to the Reference Period of 90 Days Under Treatment
Query!
Assessment method [17]
0
0
A bleeding day is a day on which sanitary protection is required. The number of bleeding days was determined for the 90 days before treatment (baseline) and for 90 days while under treatment. A negative value indicates a reduction in the number of bleeding days while under treatment compared to baseline.
Query!
Timepoint [17]
0
0
Baseline and reference period of 90 days under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7
Query!
Secondary outcome [18]
0
0
Change From Baseline in Number of Sanitary Protection Used at 90 Days of Treatment
Query!
Assessment method [18]
0
0
The number of total sanitary protection items used during the 90 days before treatment (baseline) and those used during the 90 days while under treatment was determined. A negative value indicates a reduction in the number of sanitary protection items used while under treatment compared to baseline.
Query!
Timepoint [18]
0
0
Baseline and reference period of 90 days under treatment. For patients who completed up to day 6 of treatment cycle 7, the efficacy phase started on the first day of treatment cycle 4, and continued through day 6 of treatment cycle 7
Query!
Secondary outcome [19]
0
0
Change From Baseline in Hemoglobin Concentration at Treatment Day 84
Query!
Assessment method [19]
0
0
Hemoglobin was measured before treatment and after 84 days under treatment. A positive value indicates an increase in hemoglobin from baseline at treatment day 84.
Query!
Timepoint [19]
0
0
Baseline (visit 5) and treatment day 84
Query!
Secondary outcome [20]
0
0
Change From Baseline in Hemoglobin Concentration at Treatment Day 196
Query!
Assessment method [20]
0
0
Hemoglobin was measured before treatment and after 196 days under treatment. A positive value indicates an increase in hemoglobin from baseline at treatment day 196.
Query!
Timepoint [20]
0
0
Baseline (visit 5) and treatment day 196
Query!
Secondary outcome [21]
0
0
Change From Baseline in Hematocrit at Treatment Day 196.
Query!
Assessment method [21]
0
0
Hematocrit was measured before treatment and after 196 days under treatment. A positive value indicates an increase in hematocrit from baseline at treatment day 196.
Query!
Timepoint [21]
0
0
Baseline (visit 5) and treatment day 196
Query!
Secondary outcome [22]
0
0
Change From Baseline in Ferritin Concentration at Treatment Day 84
Query!
Assessment method [22]
0
0
Ferritin was measured before treatment and after 84 days under treatment. A positive value indicates an increase in ferritin from baseline at treatment day 84.
Query!
Timepoint [22]
0
0
Baseline (visit 5, day 1) and treatment day 84
Query!
Secondary outcome [23]
0
0
Change From Baseline in Ferritin Concentration at Treatment Day 196
Query!
Assessment method [23]
0
0
Ferritin was measured before treatment and after 196 days under treatment. A positive value indicates an increase in ferritin from baseline at treatment day 196.
Query!
Timepoint [23]
0
0
Baseline (visit 5, day 1) and treatment day 196
Query!
Secondary outcome [24]
0
0
Change From Baseline in Psychological General Well-Being Index (PGWBI) Score at Treatment Day 84.
Query!
Assessment method [24]
0
0
The PGWBI questionnaire consisted of 22 questions that were answered using a 6-grade Likert scale. The minimum overall score was 22 and the maximum 132. The higher the score, the better the well-being of the patient. The observation phase was the last 4 weeks. The following 6 dimensions were derived from the questionnaire: anxiety, depressed mood, positive well-being, self-control, health, and vitality and the highest possible scores were 30, 18, 24, 18, 18, and 24, respectively.
Query!
Timepoint [24]
0
0
Baseline (visit 5, day 1) and treatment day 84
Query!
Secondary outcome [25]
0
0
Change From Baseline in Psychological General Well-Being Index (PGWBI) Score at Treatment Day 196.
Query!
Assessment method [25]
0
0
The PGWBI questionnaire consisted of 22 questions that were answered using a 6-grade Likert scale. The minimum overall score was 22 and the maximum 132. The higher the score, the better the well-being of the patient. The observation phase was the last 4 weeks. The following 6 dimensions were derived from the questionnaire: anxiety, depressed mood, positive well-being, self-control, health, and vitality and the highest possible scores were 30, 18, 24, 18, 18, and 24, respectively.
Query!
Timepoint [25]
0
0
Baseline (visit 5, day 1) and treatment day 196
Query!
Secondary outcome [26]
0
0
Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Score at Treatment Day 84
Query!
Assessment method [26]
0
0
The MFSQ was designed to measure aspects of female sexuality and asked about the patients´sexual experience during the last 4 weeks. Higher scores represent higher, more complete, or better integrated levels of female sexual function. Minimum and maximum values are 19 and 133.
Query!
Timepoint [26]
0
0
Baseline (visit 5, day 1) and treatment day 84
Query!
Secondary outcome [27]
0
0
Change From Baseline in McCoy Female Sexuality Questionnaire (MFSQ) Score at Treatment Day 196
Query!
Assessment method [27]
0
0
The MFSQ was designed to measure aspects of female sexuality and asked about the patients´sexual experience during the last 4 weeks. Higher scores represent higher, more complete, or better integrated levels of female sexual function. Minimum and maximum values are 19 and 133.
Query!
Timepoint [27]
0
0
Baseline (visit 5, day 1) and treatment day 196
Query!
Secondary outcome [28]
0
0
Change From Baseline in EuroQol 5 Dimensional (EQ-5D) Score at Treatment Day 84
Query!
Assessment method [28]
0
0
The health state classification of the EQ-5D comprises 5 questions addressing mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Patients were asked to indicate their current health state by ticking the most appropriate of 3 statements about each of the questions (ie, no problems, some problems, extreme problems). The best possible answers were (1,1,1,1,1), which equals a valuation score of 1.0. The worst possible answers were (3,3,3,3,3), which equals a score of .594.
Query!
Timepoint [28]
0
0
Baseline (visit 5, day 1) and treatment day 84
Query!
Secondary outcome [29]
0
0
Change From Baseline in EuroQol 5 Dimensional (EQ-5D) Score at Treatment Day 196
Query!
Assessment method [29]
0
0
The health state classification of the EQ-5D comprises 5 questions addressing mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. Patients were asked to indicate their current health state by ticking the most appropriate of 3 statements about each of the questions (ie, no problems, some problems, extreme problems). The best possible answers were (1,1,1,1,1), which equals a valuation score of 1.0. The worst possible answers were (3,3,3,3,3), which equals a score of .594.
Query!
Timepoint [29]
0
0
Baseline (visit 5, day 1) and treatment day 196
Query!
Secondary outcome [30]
0
0
Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 84.
Query!
Assessment method [30]
0
0
The visual analogue scale (ie, "thermometer") had endpoints of 100 (best imaginable health state) at the top, and 0 (worst imaginable health state) at the bottom. Patients rated their current health state by drawing a line from the box marked "your own health state today" to the appropriate point on the thermometer scale.
Query!
Timepoint [30]
0
0
Baseline (visit 5, day 1) and treatment day 84
Query!
Secondary outcome [31]
0
0
Change From Baseline in Visual Analogue Scale (VAS) of the EQ-5D Score at Treatment Day 196.
Query!
Assessment method [31]
0
0
The visual analogue scale (ie, "thermometer") had endpoints of 100 (best imaginable health state) at the top, and 0 (worst imaginable health state) at the bottom. Patients rated their current health state by drawing a line from the box marked "your own health state today" to the appropriate point on the thermometer scale.
Query!
Timepoint [31]
0
0
Baseline (visit 5, day 1) and treatment day 196
Query!
Secondary outcome [32]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 84.
Query!
Assessment method [32]
0
0
The patient was asked if there was any change in her employment status in the last 12 weeks and was asked to specify the number of hours per week. The proportion of participants with such changes are displayed.
Query!
Timepoint [32]
0
0
Treatment day 84
Query!
Secondary outcome [33]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Change in the Employment Status) at Treatment Day 196.
Query!
Assessment method [33]
0
0
The patient was asked if there was any change in her employment status in the last 12 weeks and was asked to specify the number of hours per week. The proportion of participants with such changes are displayed.
Query!
Timepoint [33]
0
0
Treatment day 196
Query!
Secondary outcome [34]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 84
Query!
Assessment method [34]
0
0
The patient was asked how many days and hours she missed from work during the past 12 weeks because of her problems associated with her DUB, not including the time missed to participate in this study.
Query!
Timepoint [34]
0
0
Treatment day 84
Query!
Secondary outcome [35]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Days Missed From Work) at Treatment Day 196
Query!
Assessment method [35]
0
0
The patient was asked how many days and hours she missed from work during the past 12 weeks because of her problems associated with her DUB, not including the time missed to participate in this study.
Query!
Timepoint [35]
0
0
Treatment day 196
Query!
Secondary outcome [36]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 84.
Query!
Assessment method [36]
0
0
The patient was asked to rate on a scale of 0 to 10, how much her DUB affected her productivity while she was working during the past 12 weeks, where 0 represented that her DUB had no effect on her work and 10 represented that her DUB completely prevented her from working.
Query!
Timepoint [36]
0
0
Treatment day 84
Query!
Secondary outcome [37]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Productivity While Working) at Treatment Day 196.
Query!
Assessment method [37]
0
0
The patient was asked to rate on a scale of 0 to 10, how much her DUB affected her productivity while she was working during the past 12 weeks, where 0 represented that her DUB had no effect on her work and 10 represented that her DUB completely prevented her from working.
Query!
Timepoint [37]
0
0
Treatment day 196
Query!
Secondary outcome [38]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 84
Query!
Assessment method [38]
0
0
The patient was asked to rate on a scale of 0 to 10, how much her DUB affected her ability to do her regular daily activities, other than work at a job, during the past 12 weeks, where 0 represented that her DUB had no effect on her daily activities and 10 represented that her DUB completely prevented her from doing her daily activities.
Query!
Timepoint [38]
0
0
Treatment day 84
Query!
Secondary outcome [39]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Regular Daily Activities) at Treatment Day 196.
Query!
Assessment method [39]
0
0
The patient was asked to rate on a scale of 0 to 10, how much her DUB affected her ability to do her regular daily activities, other than work at a job, during the past 12 weeks, where 0 represented that her DUB had no effect on her daily activities and 10 represented that her DUB completely prevented her from doing her daily activities.
Query!
Timepoint [39]
0
0
Treatment day 196
Query!
Secondary outcome [40]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 84
Query!
Assessment method [40]
0
0
The patient was asked if she had any unscheduled outpatient visits to a hospital because of her DUB during the past 12 weeks, not including visits that were due to her participation in this study. She was also asked to indicate the number of visits. The proportion of participants with any unscheduled outpatient visits are displayed.
Query!
Timepoint [40]
0
0
Treatment day 84
Query!
Secondary outcome [41]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit at Hospital) at Treatment Day 196
Query!
Assessment method [41]
0
0
The patient was asked if she had any unscheduled outpatient visits to a hospital because of her DUB during the past 12 weeks, not including visits that were due to her participation in this study. She was also asked to indicate the number of visits. The proportion of participants with any unscheduled outpatient visits are displayed.
Query!
Timepoint [41]
0
0
Treatment day 196
Query!
Secondary outcome [42]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit to Physician) at Treatment Day 84
Query!
Assessment method [42]
0
0
The patient was asked if she had any unscheduled outpatient visits to a physician (non-hospital medical care) because of her DUB during the past 12 weeks, not including visits that were due to her participation in this study. She was also asked to indicate the number of visits. The proportion of participants with such visits are displayed.
Query!
Timepoint [42]
0
0
Treatment day 84
Query!
Secondary outcome [43]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Unscheduled Outpatient Visit to Physician) at Treatment Day 196
Query!
Assessment method [43]
0
0
The patient was asked if she had any unscheduled outpatient visits to a physician (non-hospital medical care) because of her DUB during the past 12 weeks, not including visits that were due to her participation in this study. She was also asked to indicate the number of visits. The proportion of participants with such visits are displayed.
Query!
Timepoint [43]
0
0
Treatment day 196
Query!
Secondary outcome [44]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 84
Query!
Assessment method [44]
0
0
The patient was asked if she had any unscheduled procedures (eg, laparoscopy, laboratory tests, ultrasound) because of her DUB during the past 12 weeks. The proportion of participants with such procedures are displayed.
Query!
Timepoint [44]
0
0
Treatment day 84
Query!
Secondary outcome [45]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Additional Unscheduled Procedures) at Treatment Day 196
Query!
Assessment method [45]
0
0
The patient was asked if she had any unscheduled procedures (eg, laparoscopy, laboratory tests, ultrasound) because of her DUB during the past 12 weeks. The proportion of participants with such procedures are displayed.
Query!
Timepoint [45]
0
0
Treatment day 196
Query!
Secondary outcome [46]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 84
Query!
Assessment method [46]
0
0
The patient was asked if she received ambulatory services (eg, home help, child care) because of her DUB during the past 12 weeks, and if yes, how many hours per week. The proportion of participants with such services are displayed.
Query!
Timepoint [46]
0
0
Treatment day 84
Query!
Secondary outcome [47]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Received Ambulatory Services) at Treatment Day 196
Query!
Assessment method [47]
0
0
The patient was asked if she received ambulatory services (eg, home help, child care) because of her DUB during the past 12 weeks, and if yes, how many hours per week. The proportion of participants with such services are displayed.
Query!
Timepoint [47]
0
0
Treatment day 196
Query!
Secondary outcome [48]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (no Out-of-pocket Expenses) at Treatment Day 84
Query!
Assessment method [48]
0
0
The patient was asked to specify her out-of pocket expenses because of her DUB during the past 12 weeks, including over-the-counter medication (the name of the medication, the number of packages, and the cost per package), co-payments due to prescribed medication, and costs to travel to and from medical appointments. The proportion of participants with no out-of pocket expenses are displayed.
Query!
Timepoint [48]
0
0
Treatment day 84
Query!
Secondary outcome [49]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (no Out-of-pocket Expenses) at Treatment Day 196
Query!
Assessment method [49]
0
0
The patient was asked to specify her out-of pocket expenses because of her DUB during the past 12 weeks, including over-the-counter medication (the name of the medication, the number of packages, and the cost per package), co-payments due to prescribed medication, and costs to travel to and from medical appointments. The proportion of participants with no out-of pocket expenses are displayed.
Query!
Timepoint [49]
0
0
Treatment day 196
Query!
Secondary outcome [50]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Not Have Any Medical Treatment) at Treatment Day 84
Query!
Assessment method [50]
0
0
The patient was asked if she had any medical treatment (eg, prescribed medication, other treatment) because of her DUB during the past 12 weeks, and to specify the cost. The proportion of participants with such treatment are displayed.
Query!
Timepoint [50]
0
0
Treatment day 84
Query!
Secondary outcome [51]
0
0
Resource Use Assessment by Use of a Self Administered Questionnaire (Not Have Any Medical Treatment) at Treatment Day 196
Query!
Assessment method [51]
0
0
The patient was asked if she had any medical treatment (eg, prescribed medication, other treatment) because of her DUB during the past 12 weeks, and to specify the cost. The proportion of participants with such treatment are displayed.
Query!
Timepoint [51]
0
0
Treatment day 196
Query!
Eligibility
Key inclusion criteria
* Women 18 years or older
* And with a diagnosis of dysfunctional uterine bleeding without organic pathology
* And with at least one of the following symptoms: prolonged, frequent or excessive bleeding.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* The use of steroidal oral contraceptives, or any drug that could alter oral contraception metabolism will be prohibited during the study.
* Women with a history of endometrial ablation or dilatation and curettage within 2 months prior to study start will be excluded.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/02/2006
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/05/2008
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
231
Query!
Recruitment in Australia
Recruitment state(s)
NSW,WA
Query!
Recruitment hospital [1]
0
0
Private Practice Dr. Ian Fraser - Ashfield
Query!
Recruitment hospital [2]
0
0
King Edward Memorial Hospital - Subiaco
Query!
Recruitment postcode(s) [1]
0
0
NSW 2131 - Ashfield
Query!
Recruitment postcode(s) [2]
0
0
6008 - Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
Czech Republic
Query!
State/province [1]
0
0
Ceske Budejovice
Query!
Country [2]
0
0
Czech Republic
Query!
State/province [2]
0
0
Pardubice
Query!
Country [3]
0
0
Czech Republic
Query!
State/province [3]
0
0
Pisek
Query!
Country [4]
0
0
Czech Republic
Query!
State/province [4]
0
0
Praha 7
Query!
Country [5]
0
0
Finland
Query!
State/province [5]
0
0
Espoo
Query!
Country [6]
0
0
Finland
Query!
State/province [6]
0
0
Lahti
Query!
Country [7]
0
0
Finland
Query!
State/province [7]
0
0
Tampere
Query!
Country [8]
0
0
Finland
Query!
State/province [8]
0
0
Turku
Query!
Country [9]
0
0
Germany
Query!
State/province [9]
0
0
Baden-Württemberg
Query!
Country [10]
0
0
Germany
Query!
State/province [10]
0
0
Niedersachsen
Query!
Country [11]
0
0
Germany
Query!
State/province [11]
0
0
Sachsen
Query!
Country [12]
0
0
Germany
Query!
State/province [12]
0
0
Berlin
Query!
Country [13]
0
0
Hungary
Query!
State/province [13]
0
0
Budapest
Query!
Country [14]
0
0
Hungary
Query!
State/province [14]
0
0
Komarom
Query!
Country [15]
0
0
Hungary
Query!
State/province [15]
0
0
Miskolc
Query!
Country [16]
0
0
Netherlands
Query!
State/province [16]
0
0
Enschede
Query!
Country [17]
0
0
Netherlands
Query!
State/province [17]
0
0
Geleen
Query!
Country [18]
0
0
Netherlands
Query!
State/province [18]
0
0
Nijmegen
Query!
Country [19]
0
0
Poland
Query!
State/province [19]
0
0
Bialystok
Query!
Country [20]
0
0
Poland
Query!
State/province [20]
0
0
Lodz
Query!
Country [21]
0
0
Poland
Query!
State/province [21]
0
0
Lublin
Query!
Country [22]
0
0
Poland
Query!
State/province [22]
0
0
Poznan
Query!
Country [23]
0
0
Poland
Query!
State/province [23]
0
0
Warszawa
Query!
Country [24]
0
0
Sweden
Query!
State/province [24]
0
0
Lund
Query!
Country [25]
0
0
Sweden
Query!
State/province [25]
0
0
Stockholm
Query!
Country [26]
0
0
Sweden
Query!
State/province [26]
0
0
Uppsala
Query!
Country [27]
0
0
Ukraine
Query!
State/province [27]
0
0
Kiev
Query!
Country [28]
0
0
Ukraine
Query!
State/province [28]
0
0
Lviv
Query!
Country [29]
0
0
United Kingdom
Query!
State/province [29]
0
0
Cheshire
Query!
Country [30]
0
0
United Kingdom
Query!
State/province [30]
0
0
Luton
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
Northwood
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Bayer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00307801
Query!
Trial related presentations / publications
Fraser IS, Jensen J, Schaefers M, Mellinger U, Parke S, Serrani M. Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Contraception. 2012 Aug;86(2):96-101. doi: 10.1016/j.contraception.2011.11.011. Epub 2012 Jan 10. Fraser IS, Parke S, Mellinger U, Machlitt A, Serrani M, Jensen J. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011 Aug;16(4):258-69. doi: 10.3109/13625187.2011.591456. Fraser IS, Romer T, Parke S, Zeun S, Mellinger U, Machlitt A, Jensen JT. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod. 2011 Oct;26(10):2698-708. doi: 10.1093/humrep/der224. Epub 2011 Jul 21. Wasiak R, Filonenko A, Vanness DJ, Wittrup-Jensen KU, Stull DE, Siak S, Fraser I. Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. Int J Womens Health. 2012;4:271-8. doi: 10.2147/IJWH.S31740. Epub 2012 Jul 12. Fraser IS, Zeun S, Parke S, Wilke B, Junge W, Serrani M. Improving the objective quality of large-scale clinical trials for women with heavy menstrual bleeding: experience from 2 multi-center, randomized trials. Reprod Sci. 2013 Jul;20(7):745-54. doi: 10.1177/1933719113477492. Epub 2013 Feb 25.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bayer Study Director
Query!
Address
0
0
Bayer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Fraser IS, Jensen J, Schaefers M, Mellinger U, Par...
[
More Details
]
Journal
Fraser IS, Parke S, Mellinger U, Machlitt A, Serra...
[
More Details
]
Journal
Fraser IS, Romer T, Parke S, Zeun S, Mellinger U, ...
[
More Details
]
Journal
Wasiak R, Filonenko A, Vanness DJ, Wittrup-Jensen ...
[
More Details
]
Journal
Fraser IS, Zeun S, Parke S, Wilke B, Junge W, Serr...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT00307801
Download to PDF